Literature DB >> 15831232

Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis.

Balveen Kaur1, Fatima W Khwaja, Eric A Severson, Shannon L Matheny, Daniel J Brat, Erwin G Van Meir.   

Abstract

Glioblastomas, like other solid tumors, have extensive areas of hypoxia and necrosis. The importance of hypoxia in driving tumor growth is receiving increased attention. Hypoxia-inducible factor 1 (HIF-1) is one of the master regulators that orchestrate the cellular responses to hypoxia. It is a heterodimeric transcription factor composed of alpha and beta subunits. The alpha subunit is stable in hypoxic conditions but is rapidly degraded in normoxia. The function of HIF-1 is also modulated by several molecular mechanisms that regulate its synthesis, degradation, and transcriptional activity. Upon stabilization or activation, HIF-1 translocates to the nucleus and induces transcription of its downstream target genes. Most important to gliomagenesis, HIF-1 is a potent activator of angiogenesis and invasion through its upregulation of target genes critical for these functions. Activation of the HIF-1 pathway is a common feature of gliomas and may explain the intense vascular hyperplasia often seen in glioblastoma multiforme. Activation of HIF results in the activation of vascular endothelial growth factors, vascular endothelial growth factor receptors, matrix metalloproteinases, plasminogen activator inhibitor, transforming growth factors alpha and beta, angiopoietin and Tie receptors, endothelin-1, inducible nitric oxide synthase, adrenomedullin, and erythropoietin, which all affect glioma angiogenesis. In conclusion, HIF is a critical regulatory factor in the tumor microenvironment because of its central role in promoting proangiogenic and invasive properties. While HIF activation strongly promotes angiogenesis, the emerging vasculature is often abnormal, leading to a vicious cycle that causes further hypoxia and HIF upregulation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15831232      PMCID: PMC1871894          DOI: 10.1215/S1152851704001115

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  185 in total

1.  HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression.

Authors:  E Laughner; P Taghavi; K Chiles; P C Mahon; G L Semenza
Journal:  Mol Cell Biol       Date:  2001-06       Impact factor: 4.272

2.  Neuropilin-1 expression by tumor cells promotes tumor angiogenesis and progression.

Authors:  H Q Miao; P Lee; H Lin; S Soker; M Klagsbrun
Journal:  FASEB J       Date:  2000-12       Impact factor: 5.191

Review 3.  Glomeruloid microvascular proliferation orchestrated by VPF/VEGF: a new world of angiogenesis research.

Authors:  D J Brat; E G Van Meir
Journal:  Am J Pathol       Date:  2001-03       Impact factor: 4.307

4.  Mitogen-activated protein kinase kinase inhibitor PD98059 blocks the trans-activation but not the stabilization or DNA binding ability of hypoxia-inducible factor-1alpha.

Authors:  E Hur; K Y Chang; E Lee; S K Lee; H Park
Journal:  Mol Pharmacol       Date:  2001-05       Impact factor: 4.436

5.  Erythropoietin and erythropoietin receptor in human ischemic/hypoxic brain.

Authors:  A L Sirén; F Knerlich; W Poser; C H Gleiter; W Brück; H Ehrenreich
Journal:  Acta Neuropathol       Date:  2001-03       Impact factor: 17.088

6.  Processing of immunosuppressive pro-TGF-beta 1,2 by human glioblastoma cells involves cytoplasmic and secreted furin-like proteases.

Authors:  J Leitlein; S Aulwurm; R Waltereit; U Naumann; B Wagenknecht; W Garten; M Weller; M Platten
Journal:  J Immunol       Date:  2001-06-15       Impact factor: 5.422

Review 7.  The transforming growth factor-beta signaling pathway in tumorigenesis.

Authors:  R Wieser
Journal:  Curr Opin Oncol       Date:  2001-01       Impact factor: 3.645

8.  iNOS expression inhibits hypoxia-inducible factor-1 activity.

Authors:  J H Yin; D I Yang; G Ku; C Y Hsu
Journal:  Biochem Biophys Res Commun       Date:  2000-12-09       Impact factor: 3.575

9.  Hypoxia promotes fibrogenesis in human renal fibroblasts.

Authors:  J T Norman; I M Clark; P L Garcia
Journal:  Kidney Int       Date:  2000-12       Impact factor: 10.612

10.  Mutant epidermal growth factor receptor enhances induction of vascular endothelial growth factor by hypoxia and insulin-like growth factor-1 via a PI3 kinase dependent pathway.

Authors:  K Clarke; K Smith; W J Gullick; A L Harris
Journal:  Br J Cancer       Date:  2001-05-18       Impact factor: 7.640

View more
  251 in total

1.  A self-powered, one-step chip for rapid, quantitative and multiplexed detection of proteins from pinpricks of whole blood.

Authors:  Jun Wang; Habib Ahmad; Chao Ma; Qihui Shi; Ophir Vermesh; Udi Vermesh; James Heath
Journal:  Lab Chip       Date:  2010-10-06       Impact factor: 6.799

2.  Myeloid biomarkers associated with glioblastoma response to anti-VEGF therapy with aflibercept.

Authors:  John F de Groot; Yuji Piao; Hai Tran; Mark Gilbert; Hua-Kang Wu; Jun Liu; B Nebiyou Bekele; Tim Cloughesy; Minesh Mehta; H Ian Robins; Andrew Lassman; Lisa DeAngelis; Kevin Camphausen; Alice Chen; W K A Yung; Michael Prados; Patrick Y Wen; John V Heymach
Journal:  Clin Cancer Res       Date:  2011-06-01       Impact factor: 12.531

3.  Gene expression analysis identifies potential biomarkers of neurofibromatosis type 1 including adrenomedullin.

Authors:  Trent R Hummel; Walter J Jessen; Shyra J Miller; Lan Kluwe; Victor F Mautner; Margaret R Wallace; Conxi Lázaro; Grier P Page; Paul F Worley; Bruce J Aronow; Elizabeth K Schorry; Nancy Ratner
Journal:  Clin Cancer Res       Date:  2010-08-25       Impact factor: 12.531

4.  The tumour suppressor C/EBPδ inhibits FBXW7 expression and promotes mammary tumour metastasis.

Authors:  Kuppusamy Balamurugan; Ju-Ming Wang; Hsin-Hwa Tsai; Shikha Sharan; Miriam Anver; Robert Leighty; Esta Sterneck
Journal:  EMBO J       Date:  2010-11-12       Impact factor: 11.598

5.  Sulfonamides as a new scaffold for hypoxia inducible factor pathway inhibitors.

Authors:  Chalet Tan; Rita G de Noronha; Narra S Devi; Adnan A Jabbar; Stefan Kaluz; Yuan Liu; Suazette Reid Mooring; K C Nicolaou; Binghe Wang; Erwin G Van Meir
Journal:  Bioorg Med Chem Lett       Date:  2011-06-28       Impact factor: 2.823

6.  Expression of vascular endothelial growth factor receptor 2 (VEGFR-2), inducible nitric oxide synthase (iNOS), and Ki-M1P in skull base chordoma: a series of 145 tumors.

Authors:  R Akhavan-Sigari; M R Gaab; V Rohde; A Brandis; H Tezval; M Abili; K von Eckardstein; H Ostertag
Journal:  Neurosurg Rev       Date:  2013-09-03       Impact factor: 3.042

7.  Evidence for transcriptional regulation of the glucose-6-phosphate transporter by HIF-1alpha: Targeting G6PT with mumbaistatin analogs in hypoxic mesenchymal stromal cells.

Authors:  Simon Lord-Dufour; Ian B Copland; Louis-Charles Levros; Martin Post; Abhirup Das; Chaitan Khosla; Jacques Galipeau; Eric Rassart; Borhane Annabi
Journal:  Stem Cells       Date:  2009-03       Impact factor: 6.277

8.  Quinacrine synergistically enhances the antivascular and antitumor efficacy of cediranib in intracranial mouse glioma.

Authors:  Merryl R Lobo; Sarah C Green; Matthias C Schabel; G Yancey Gillespie; Randall L Woltjer; Martin M Pike
Journal:  Neuro Oncol       Date:  2013-10-03       Impact factor: 12.300

9.  The Bmi-1/NF-κB/VEGF story: another hint for proteasome involvement in glioma angiogenesis?

Authors:  Panagiotis J Vlachostergios; Christos N Papandreou
Journal:  J Cell Commun Signal       Date:  2013-03-15       Impact factor: 5.782

10.  Regional hypoxia in glioblastoma multiforme quantified with [18F]fluoromisonidazole positron emission tomography before radiotherapy: correlation with time to progression and survival.

Authors:  Alexander M Spence; Mark Muzi; Kristin R Swanson; Finbarr O'Sullivan; Jason K Rockhill; Joseph G Rajendran; Tom C H Adamsen; Jeanne M Link; Paul E Swanson; Kevin J Yagle; Robert C Rostomily; Daniel L Silbergeld; Kenneth A Krohn
Journal:  Clin Cancer Res       Date:  2008-05-01       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.